Mar.03 -- Emily Chang highlights Astra, the latest startup company trying to take part in the modern-day space race. Astra CEO Chris Kemp has decided to take the company public through SPAC to raise enough money to help the company get to space.
Mar.03 -- Emily Chang highlights Astra, the latest startup company trying to take part in the modern-day space race. Astra CEO Chris Kemp has decided to take the company public through SPAC to raise enough money to help the company get to space.
Bilia has today concluded an agreement to acquire an authorised Mercedes dealer, Upplands Motor Stockholm AB, who conduct sales and service operations for Mercedes cars, transport vehicles and trucks at four facilities in the Stockholm area in Sweden. The agreement is subject to approval by the Swedish competition authority. Bilia is expecting to take over the operations on 1 July 2021. The business that is acquired reported for 2020 a turnover of about SEK 1,200 M and an operating profit of SEK 48 M. The number of employees is about 250. The operation’s capital employed and agreed surplus values amount to about SEK 220 M. The Bilia Group’s capital employed and net debt are estimated to increase, related to the acquisition, by about SEK 350 M. Per Avander, Bilia’s MD and CEO, comments:”I’m very happy and proud that Bilia in the future will work with Mercedes, which will be an excellent addition to Bilia’s current car brand portfolio. Through the acquisition, we are also adding a new and interesting business area to Bilia in the form of heavy trucks, in which Mercedes is one of Europe’s largest and most successful players.” Oskar Lindström, Chairman of the Board at Upplands Motor Holding, comments:”We are very happy to have Bilia as new owner of Upplands Motor’s Mercedes operations. Bilia’s customer focus, competence and experience are important in the further development of the Mercedes business. A business that we are proud to have been entrusted with from Mercedes-Benz to develop in Stockholm. Bilia becomes a strong partner to Mercedes-Benz to continue that work.” Niels Kowollik, MD Mercedes Sweden, comments:”I’m pleased that Bilia, as one of Sweden’s most experienced and knowledgeable players, who also has experience of working with premium brands, has acquired Upplands Motor. They are good at offering concepts that are appreciated by customers, which we see as an important part of future car sales. I look forward to a good collaboration with Bilia.” Gothenburg, April 23, 2021 Bilia AB (publ) This is information that Bilia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on April 23, 2021, at 08:10 CEST. For information please contact: Per Avander, Managing Director and CEO, +46 (0)10 497 70 00, firstname.lastname@example.org Kristina Franzén, CFO, +46 (0)10 497 73 40, email@example.com Facts about the Bilia Group Bilia is one of Europe’s largest car dealers with a leading position within service and sales of cars and transport vehicles. Bilia has about 140 facilities in Sweden, Norway, Germany, Luxembourg and Belgium. Bilia sells cars of the brand Volvo, BMW, Toyota, Renault, Lexus, MINI, Dacia, Alpine and transport vehicles of the brand Renault, Toyota and Dacia. Bilia offers new and used cars, e-commerce, spare parts and store sales, service and repair workshops, tyres and car glass and financing, insurance, car washes, fuel stations and car dismantling under the same roof, which gives a unique customer offer. Bilia reported a turnover of about SEK 30 Bn in 2020 and had about 4,700 employees. Attachment Bilia acquires Upplands Motor Stockholm AB, a Mercedes dealer for cars, transport vehicles and trucks
Aiea, Hawaii, April 23, 2021 (GLOBE NEWSWIRE) -- Slick Vision Tattoo & Laser Removal is home to Aiea, Hawaii’s most talented tattoo artists. The up-and-coming tattoo and laser removal studio is a one-stop-shop for anyone looking to get a new tattoo, remove an unwanted tattoo, or modify an existing tattoo. Slick Vision Tattoo & Laser Removal specializes in removing tattoo regret with complete tattoo removal, tattoo lightening for cover-ups, and selective removal for partial modification. Slick Vision Tattoo & Laser Removal uses the Astanza Duality laser to perform all laser tattoo removal services and help residents in the island of Oahu achieve their skin’s desired look. “Slick Vision Tattoo & Laser Removal was founded in hopes of helping people feel happy and comfortable in their skin. As tattoo artists, we love seeing the power that tattoos have on an individual. However, we also know the negative impact an unwanted tattoo or old can have on a person,” said Jayson Ramoran, owner. “With laser tattoo removal, we can erase tattoos that people no longer identify with, fade tattoos to create better cover-ups, and remove a specific part of a tattoo, like a name, without touching the surrounding ink. We are excited to introduce the Astanza Duality to local residents and continue delivering the best artwork.” The Astanza Duality is a cutting-edge Q-switched Nd:YAG device that uses ultra-quick pulse durations and intense peak power to safely shatter unwanted ink in the skin. The Duality is revered as one of the best lasers on the market and is trusted by leading physicians, medical spas, tattoo artists, and laser technicians worldwide. The Duality’s 532 nm and 1064 nm wavelengths can target and remove a wide variety of tattoo colors and are safe to use on all skin types. “Jayson and the Slick Vision Tattoo & Laser Removal team are a group of passionate tattoo lovers,” said Opal Taskila, Astanza Sales Representative. “Their investment in the Duality is proof of their commitment to delivering the best tattoo and laser removal results throughout the island of Oahu.” About Slick Vision Tattoo & Laser Removal Slick Vision Tattoo & Laser Removal is a full-service tattoo studio and laser tattoo removal shop located in Aiea, Hawaii. They provide expert tattooing, complete tattoo removal, selective tattoo removal, and fading for cover-ups. Their laser technicians received expert training from New Look Laser College, the world’s leading laser tattoo removal training program, and received the designations of Certified Laser Specialist (CLS) and Laser Safety Officer (LSO). To schedule a consultation or learn more about their services, visit https://www.slickvisiontattooandlaserremoval.com/ and follow them on Instagram. Slick Vision Tattoo & Removal is located at the Aiea Commercial Center, 99-185 Moanalua Rd. Suite 103 Aiea, Hawaii 96701. About Astanza Laser Astanza is the leader in lasers for tattoo removal, hair removal, and additional aesthetic procedures. In addition to delivering cutting-edge medical laser devices such as the Duality, Trinity, MeDioStar, and DermaBlate systems, Astanza offers its customers a complete range of training, marketing, and business consulting services to achieve success in this growing field. Astanza is an award-winning company that has received several accolades from leading industry organizations, including MyFaceMyBody and Aesthetic Everything. They are also certified as a “Great Place to Work”. Astanza Laser is headquartered in Dallas, TX, with customers throughout North America and Europe. For product, investor, or press information, call (800) 364-9010, or visit https://astanzalaser.com/. Connect with Astanza on LinkedIn, Facebook, Instagram, Twitter, and YouTube. CONTACT: Astanza Laser Astanza Laser (800) 364-9010 firstname.lastname@example.org
‘What I saw in the video was another George Floyd,’ attorney says
Thought George was just the patron saint of England? Think again
Šiaulių Bankas AB, company code 112025254, domicile address Tilžės st. 149, LT-76348 Šiauliai, Lithuania.The General meeting of shareholders held on 31 March 2021 approved allocation of the profit of Šiaulių Bankas AB which included a pay-out of dividends - 0.0055 euro shall be paid for each ordinary registered share with a nominal value of 0.29 euro. Dividends shall be paid out to persons who were the shareholders of Šiaulių Bankas AB at the end of the record day - 15 April 2021. The Bank shall pay out dividends on 28 April 2021 in compliance with the following procedure:- those shareholders whose shares are being accounted in the securities accounts with banks and financial brokerage companies rendering investment services will receive an amount of dividends after deduction of Personal Income Tax or Corporate Profit Tax in compliance with the laws of the Republic of Lithuania which shall be transferred to the accounts with the respective banks or financial brokerage companies; - for shareholders whose shares are accounted for in Šiaulių Bankas AB in the issuer's accounting, the amount of dividends, after deducting personal income tax or income tax in accordance with the laws of the Republic of Lithuania, will be transferred to the account with Šiaulių Bankas AB specified by the shareholder. If the shareholder has not specified an account with Šiaulių Bankas AB for the transfer of dividends, he/she must submit an application for the transfer of dividends. Applications are accepted from 28 April 2021 in all customer service points of Šiaulių Bankas AB. As long as the quarantine regime is in force, in accordance with security requirements, before going to the customer service department, it is necessary to register for a visit on-line at www.sb.lt or by phone 1813. Applications for dividend transfer can also be submitted via the bank's online banking. Taxation of dividends:- Dividends of natural persons residents of the Republic of Lithuania and foreign countries shall be subject to 15 per cent of the Personal Income Tax rate; - Dividends of legal entities residents of the Republic of Lithuania and foreign countries shall be subject to 15 per cent of the Corporate Profit Tax rate, unless otherwise provided for in the laws. Additional information:Director of Securities Accounting Department Jolanta Dobiliauskienė+370 41 595 669, e-mail email@example.com
India’s Covid nightmare – photo essay. As a new global record 314,835 for new Covid cases is set in India, hospitals are running out of oxygen and bodies are stacking up in morgues
From Line of Duty-core to fake houseplants: this week’s fashion trends. What’s hot and what’s not in fashion this week
Prince Charles’s model village architecture? Give me brutalism any day. There is a large cohort of people who despise the look, but I am a broad church when it comes to architecture
House of Cardin review – genial fashion futurist with an eye for expansion. Aside from some breathless celebrity endorsements, Pierre Cardin comes across as a designer ahead of his time, explored in a respectful, decent doc
Opponents of LTNs claim they delay emergency services – but look at the facts. One thing is clear: there is virtually no evidence that low-traffic neighbourhood schemes hold up emergency vehicles
This war graves report shows Britain must face its colonial past with honesty. Hundreds of thousands of soldiers who died for Britain went unremembered, simply because of their race
Oslo, 23 April 2021: Yara reports improved first-quarter results, as improved pricing more than offset the impact of higher energy cost. First-quarter net income was USD 14 million (USD 0.05 per share) compared with USD -119 million (USD -0.43 per share) a year earlier. The main elements of the first-quarter results are: EBITDA excl. special items1 was USD 585 million, up from 504 million a year earlier, as improved pricing more than offset higher natural gas costContinued premium product growthUSD 2.7 billion free cash flow2 the last 12 months8.6% ROIC3, up from 6.9% a year earlier “Yara delivers its eleventh consecutive quarter with improved capital returns, with EBITDA excluding special items up 16%, and continued growth in premium sales. The Yara organization continues to perform well in a demanding environment,” said Svein Tore Holsether, President and Chief Executive Officer of Yara. "Our cash flow also continued to improve, with 2.7 billion US dollars of free cash flow generated over the last four quarters. We will consider further cash returns in the coming quarters, in line with Yara’s capital allocation policy,” said Holsether. First-quarter operating income was USD 322 million, compared with USD 248 million a year earlier. Earnings per share excluding currency effects and special items was USD 0.80, compared with USD 0.39 per share in first quarter 2020. EBITDA excluding special items was USD 585 million, compared with USD 504 million a year earlier.Yara’s industry fundamentals are robust, as the twin challenges of resource efficiency and environmental footprint require significant transformations within both agriculture and the hydrogen economy. Yara’s leading food solutions and ammonia positions are well placed to both address and create business opportunities from these challenges.Link to report, presentation and webcast 23 April at 12:00 CEST:https://www.yara.com/investor-relations/latest-quarterly-report/ 1) For definition and reconciliation of EBITDA excl. special items, see APM section in 1Q report page 272) Net cash provided by operating activities minus net cash used in investment activities, see cash flow statement in 1Q report page 143) Return on invested capital, for definition and reconciliation of ROIC see APM section in 1Q report page 29Note on Alternative performance measures: Alternative performance measures aredefined, explained and reconciled to the Financial statements in the APM sectionof the Quarterly report on pages 28-33.ContactThor Giæver, SVP Investor RelationsMobile: (+47) 480 75 356E-mail: firstname.lastname@example.orgJosiane Kremer, Director External CommunicationsMobile: (+47) 481 80 451E-mail: email@example.comAbout Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a climate positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable food value chain. To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming, and work closely with partners throughout the food value chain to improve the efficiency and sustainability of food production. Through our focus on clean ammonia production, we aim to enable the hydrogen economy, driving a green transition of shipping, fertilizer production and other energy intensive industries. Founded in 1905 to solve the emerging famine in Europe, Yara has established a unique position as the industry’s only global crop nutrition company. We operate an integrated business model with around 17,000 employees and operations in over 60 countries, with a proven track record of strong returns. In 2020, Yara reported revenues of USD 11.6 billion.www.yara.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments Yara 1Q 2021 Report Yara 1Q 2021 Presentation
SCANFIL PLC INTERIM REPORT 23 APRIL 2021 9.00 A.M. Scanfil Group’s Interim Report for 1 January – 31 March 2021: Brisk trend in demand continued from the end of 2020 January - March Turnover totalled EUR 163.3 million (Q1 2020: 144.1), an increase of 13.4%Operating profit EUR 10.0 (8.6) million, 6.1% (6.0%) of turnover, an increase of 15.5%Net profit was EUR 7.6 (7.5) millionEarnings per share were EUR 0.12 (0.12)Dividend of EUR 0.17 per share for year 2020 to be paid on May 3, an increase in dividend for 8th consecutive year Future Outlook Scanfil estimates that its turnover for 2021 will be EUR 600 – 640 million and its adjusted operating profit will be EUR 40 – 44 million. The guidance for 2021 involves uncertainty arising from the potential negative impact of the availability of certain materials, especially semiconductors, and the COVID-19 pandemic on customer demand and the delivery capability of the component supply chain. Long-Term Target Scanfil’s long-term target: In 2023, Scanfil is organically aiming for EUR 700 million turnover and 7% operating profit. Key Figures Q1/2021Q1/2020Change%2020Turnover, EUR million163.3144.113.4 %595.3Operating Profit, EUR million10.08.615.5 %44.4Operating Profit, Adjusted, EUR million10.08.615.5 %39.1Operating Profit, %6.16.0 7.5Operating Profit, Adjusted, %6.16.0 6.6Net Profit, EUR million22.214.171.124 %36.9Net Profit, Adjusted, EUR million126.96.36.199 %32.5Earnings per Share, EUR0.120.121.0 %0.57Earnings per Share, Adjusted, EUR0.120.121.0 %0.50Return on Equity, %16.317.9 21.1Return on Equity, Adjusted, %16.317.9 18.4Equity Ratio, %52.148.8 54.3Net Gearing, %5.925.0 9.9Net Cash Flow from Operations, EUR million7.75.930.5 %35.2Employees (Average)3,2253,522-8.4 %3,387 CEO Petteri JokitaloThe turnover for the first quarter was EUR 163.3 million, an increase of 13% year-on-year. The customer demand recovery that had already started in the latter part of 2020 continued positively during the quarter. Demand for products related to sustainable energy, indoor climate, automation, collection solutions and elevators developed especially strongly. The trading business, which is now expected to be completed, was still contributing about EUR 8.1 million to sales during the quarter. COVID-19 is not over yet, and we successfully continued the fight against it; the performance of our personnel and factories has remained high this year. Although the availability of certain materials was critical, we did not suffer from any major material restrictions during the quarter. Continuous attention was paid and lot of actions taken to mitigate the risks and ensure the materials for production. Profitability developed as expected. The operating profit for the quarter was EUR 10.0 million, 6.1% of turnover and an increase of 16% on the previous year. A strong sales volume, especially in March, supported profitability, especially in factories in China, Poland and Estonia. However, low profit trading sales and Hamburg production transfer with an ongoing factory ramp down required extra resources and costs, which negatively impacted the operating profit margin slightly. Scanfil’s financial position is strong, allowing the planned investments and enabling flexibility for opportunities. In the first quarter, the net cash flow from operations, before investments and financial items, was EUR 7.7 (5.6) million. The equity ratio was 52.1%, and net gearing 5.9%. We continue the year with confidence. We have seen customers’ forecasts gradually rising, bringing confidence in demand. Key risks are associated with the continuing coronavirus pandemic and the availability of certain materials. We have identified these risks and launched appropriate mitigation actions. We are keeping our guidance unchanged and expect our turnover for 2021 to be EUR 600 – 640 million and our operating profit to be EUR 40 – 44 million. We’ve had a good start to the year! I want to thank our committed personnel for a job well done, and our customers for their support and trust. Financial Development The Group’s turnover for January – March was EUR 163.3 (144.1) million, an increase of 13.4% compared to the previous year. Turnover by customer segment developed as follows: Advanced Consumer Applications segments turnover increased compared to the previous year by EUR 11.7 million (37.7%). The key drivers behind the strong growth were new customers’ ramp-ups, good demand in elevator products and hand-over solutions. Automation & Safety segments turnover decreased compared to the previous year by EUR 3.4 million (-8.9 %). However the turnover has been growing steadily since the third quarter of 2020. This increase came broadly from the segment’s customers. Connectivity segments turnover increased compared to the previous year by EUR 0.7 million (9.2%). This sale growth came broadly from the segment’s customers.Energy & Cleantech segments turnover increased compared to the previous year by EUR 5.9 million (17.1%). The key drivers behind the strong growth were good demand in reverse vending machines, energy systems and indoor climate control systems. Medtech & Life Science segments turnover increased compared to the previous year by EUR 2.1 million (7.8%). The turnover has developed steadily since the second quarter of 2020. The Group’s operating profit for January – March was EUR 10.0 (8.6) million, 6.1% (6.0%) of turnover. The increase in operating profit is mainly due to higher net sales. The net profit for the review period was EUR 7.6 (7.5) million. Earnings per share for the review period were EUR 0.12 (0.12). Return on investment was 17.5% (17.8%). The Group’s effective tax rate was 18.2% (14.1%). Publication of financial releasesThis stock exchange release is a summary of the Scanfil Group’s Interim Report 1 January – 31 March 2021 and includes the most relevant information of the report. The complete report is attached to this release as a pdf file and is also available on the company’s website at www.scanfil.com. Webcast Q1 resultsA results conference, conducted in Finnish, will be held at 10:00 am as a webcast. You can register and join the webcast at https://scanfil.videosync.fi/2021-q1-tulos/register. Prior to the conference, the presentation material will be made available in English in here.SCANFIL PLCPetteri JokitaloCEOAdditional information: CEO Petteri JokitaloTel +358 8 4882 111Scanfil is an international manufacturing partner and system supplier for the electronics industry with 40 years of experience in demanding manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability. Typical Scanfil products are modules or integrated products for e.g. self-service application, automation systems, wireless connectivity modules, climate control systems, collection and shorting systems, analysers and environmental measurement solutions. Scanfil services are used by numerous international automation, safety, energy, cleantech, connectivity and health service providers, as well as companies operating in the field of urbanisation. Scanfil’s network of factories consists of 10 production units in Europe, Asia and North America. Not to be published or distributed, directly or indirectly, in any country where its distribution or publication is unlawful. Forward looking statements: certain statements in this stock exchange release may constitute "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Scanfil plc to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this stock exchange release, such statements use such words as "may," "will," "expect," "anticipate," "project," "believe," "plan" and other similar terminology. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of Scanfil plc to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The forward-looking information contained in this stock exchange release is current only as of the date of this stock exchange release. There should not be an expectation that such information will in all circumstances be updated, supplemented or revised, except as provided by the law or obligatory regulations, whether as a result of new information, changing circumstances, future events or otherwise Attachment Scanfil Q1_2021 interim report
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Hamilton, Bermuda, 23 April 2021. Reference is made to the stock exchange notice from Avance Gas Holding Ltd (the "Company", OSE ticker code "AGAS") on 8 April 2021 regarding the successful completion of the NOK 555 million private placement at a price of NOK 43 per share (the "Private Placement") and a conditional subsequent offering of up to 644,950 new common shares in the Company (the "Subsequent Offering"). Since the announcement of the successful completion of the Private Placement, the Company's shares have traded on the Oslo Stock Exchange, with significant trading volumes, at prices below the subscription price in the Private Placement of NOK 43 per share. Accordingly, any shareholders wishing to neutralize the dilutive effect of the Private Placement have had the opportunity to purchase shares in the Company in the market, at prices below what would have been the subscription price in the Subsequent Offering. The Company has therefore resolved to cancel the Subsequent Offering. For further queries, please contact:Randi Navdal Bekkelund, CFOTel: 47 22 00 48 29Email: firstname.lastname@example.orgKristian Sørensen, CEOTel: +47 22 00 48 10Email: email@example.com About Avance Gas Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen modern ships and four Dual Fuel LPG newbuildings due for delivery in Q4 2021, Q1 2022, Q4 2022 and Q1 2023. For more information about Avance Gas, please visit: www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
What's next in the village?
Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 23 April 2021 Vast Resources plc(‘Vast’ or the ‘Company’) Issue of Equity Total Voting Rights Further to the announcement of 20 April 2021, and the Proposed Capital Reorganisation, the Company now announces the issue of 98 ordinary shares of 0.1p each at 0.1p per share in the Company (the “Shares”) in order that the total number of ordinary shares in issue is exactly divisible by 100, thus enabling the Capital Reorganisation to be effected. Application is being made for the Shares, which will rank pari passu with all other existing ordinary shares, to be admitted to trading on AIM (“Admission”). Admission is expected on or around 29 April 2021. At Admission, the Company's issued share capital is expected to consist of 21,300,489,500 ordinary shares with a nominal value of 0.1p each, with voting rights ("Ordinary Shares"). The Company does not hold any Ordinary Shares in Treasury and accordingly the total number of Ordinary Shares with voting rights is expected to be 21,300,489,500. Subject to the Resolution put to the General Meeting on 5 May 2021 relating to the Capital Reorganisation being approved, application has also been made for the resultant expected entire issued share capital comprising 213,004,895 new ordinary shares with a nominal value of 0.1p each in their consolidated form (the “New Ordinary Shares”) to be admitted to trading on AIM (“New Ordinary Shares Admission”). Subject as aforesaid, the New Ordinary Shares Admission would take place at 08.00 on 6 May 2021. **ENDS** For further information, visit www.vastplc.com, follow the Company on Twitter @vast_resources and LinkedIn, or please contact: Vast Resources plcAndrew Prelea – CEO Andrew Hall – CCO www.vastplc.com+44 (0) 20 7846 0974Beaumont Cornish - Financial & Nominated Adviser Roland Cornish James Biddlewww.beaumontcornish.com+44 (0) 20 7628 3396SP Angel Corporate Finance LLP – Joint Broker Richard MorrisonCaroline Rowe www.spangel.co.uk +44 (0) 20 3470 0470Axis Capital Markets Limited – Joint Broker Richard Hutchison www.axcap247.com +44 (0) 20 3206 0320St Brides Partners Limted Susie Geliher www.stbridespartners.co.uk +44 (0) 20 7236 1177
Kenmare Resources plc (“Kenmare” or “the Group”) 23 April 2021 Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) 1Details of the person discharging managerial responsibilities/person closely associateda)NameELAINE DORWARD-KING2Reason for the notificationa)Position/statusDIRECTORb)Initial Notification AmendmentINITIAL NOTIFICATION3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameKENMARE RESOURCES PLC b)LEI635400ETHWP1EKJMDO164Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type ofinstrumentORDINARY SHARES OF €0.001 EACHIdentification codeIE00BDC5DG00b)Nature of the transactionPURCHASE OF SHARESc)Price(s) and volume(s)Price(s)Volume(s)STG£4.3666400 shares d)Aggregated information— Aggregated volume— PriceORDINARY SHARES PURCHASED AT STG£4.366 EACH e)Date of the transaction2021-04-21f)Place of the transactionLONDON STOCK EXCHANGEg)Additional Information
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group. “Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” commented Mike Wells, MD, a pulmonologist and Principal Investigator at the University of Alabama at Birmingham Hospital. Ensifentrine is a first-in-class product candidate with both bronchodilator and anti-inflammatory activities in one compound, currently in Phase 3 clinical development for the treatment of Chronic Obstructive Pulmonary Disease (“COPD”). Clinical data from studies of ensifentrine in the treatment of other respiratory diseases have shown ensifentrine improved lung function, reduced inflammation in the lungs* and reduced symptoms of cough and sputum production. Ensifentrine has been well tolerated in clinical trials involving more than 1,300 people. Study Design The study was a double-blind, placebo controlled, unpowered pilot study designed to evaluate inhaled ensifentrine on key outcomes in patients with COVID-19 when added on to standard of care therapies, which included remdesivir and dexamethasone. The study randomized 30 patients to receive ensifentrine and 15 to placebo. Patient Population: 45 hospitalized patients with COVID-19. Single center study at University of Alabama at Birmingham.Dose/Duration: patients randomized to receive 2 mg of pMDI ensifentrine or placebo, twice-daily for up to 29 days or until discharge if this occurred before 29 days. The clinical status of all patients was evaluated daily until discharge and at Day 29 and Day 60.Primary endpoint: proportion of patients recovered (not hospitalized) from COVID-19 over 29 days.Other endpoints included: safety and tolerability, time to recovery, proportion of patients with 1- and 2-point improvement on an ordinal scale, proportion of patients progressing to mechanical ventilation, duration of hospitalization, duration and incidence of oxygen use, re-hospitalization, and mortality. Further information about this study can be found at www.clinicaltrials.gov, NCT04527471. *Franciosi LG, et al., Lancet Respir Med 2013 For further information please contact: Verona Pharma plcUS Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Communicationsinfo@veronapharma.com Argot Partners(US Investor Enquiries)Tel: +firstname.lastname@example.orgKimberly Minarovich / Michael Barron Optimum Strategic Communications(International Media and European Investor Enquiries)Tel: +44 (0)203 950 email@example.comMary Clark / Eva Haas / Shabnam Bashir About Ensifentrine Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”). This dual inhibition enables it to combine both bronchodilator and anti-inflammatory effects in one compound. Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), which is beneficial in reducing mucous viscosity and improving mucociliary clearance. Ensifentrine’s mechanism of action has the potential to alleviate respiratory symptoms such as breathlessness and cough and work against inflammation associated with COPD or inflammation triggered by viruses. Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and symptoms, including breathlessness, in Verona Pharma’s Phase 2 clinical studies in patients with moderate to severe Chronic Obstructive Pulmonary Disease (“COPD”). In addition, nebulized ensifentrine showed further improved lung function and reduced lung volumes in COPD patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. Ensifentrine has been well tolerated in clinical trials involving more than 1,300 subjects to date. About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release, operational review, outlook and financial review contain forward-looking statements. All statements contained in this press release with respect to our operational review, outlook and financial review that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development of ensifentrine and the progress and timing of clinical trials and data, the goals and design of clinical trials, the potential for ensifentrine to be a first-in-class phosphodiesterase 3 and 4 inhibitor and to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and anti-inflammatory effects in one compound, the potential of ensifentrine to alleviate respiratory symptoms such as breathlessness and cough and work against inflammation associated with COPD or inflammation triggered by viruses, and the potential applications of ensifentrine in the treatment of COPD, cystic fibrosis, asthma and other respiratory diseases. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts and the completion of our clinical trials; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel; material differences between our “top-line” data and final data; our reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods; and our vulnerability to natural disasters, global economic factors and other unexpected events, including health epidemics or pandemics like the novel coronavirus (COVID-19), which has and may continue to adversely impact our business. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
First quarter Net sales for the first quarter reached SEK 455 m (361), corresponding to an increase of 26%. Currency translations had a negative effect of SEK 29 m on net sales Order intake was SEK 565 m (401), corresponding to an increase of 41% Operating profit reached SEK 114 m (67) equal to a 25.0% (18.5) operating margin Profit after taxes totalled SEK 94 m (48) and earnings per share was SEK 1.93 (1.01) Cash flow from operating activities amounted to SEK 132 m (55) Last twelve months Net sales for the last twelve months reached SEK 1,560 m (1,500), corresponding to a 4% increase. Currency translations had a negative effect of SEK 51 m on net sales Order intake was SEK 1,611 m (1,484), corresponding to an increase of 9% Operating profit was SEK 335 m (250), equal to a 21.4% (16.7) operating margin Profit after taxes totalled SEK 266 m (212) and earnings per share was SEK 5.70 (4.56) Cash flow from operating activities amounted to SEK 447 m (257) Comment from the CEOFull speed ahead!At the end of last year, we saw a more positive market climate and an increased demand for HMS products. The increased demand has continued in the first quarter of 2021, even stronger than expected. We released preliminary figures on order intake, sales and profitability as early as April 8, and can now confirm and elaborate on this positive situation. The quarter’s order intake was very strong and amounted to SEK 565 m, an increase of 41% compared to the same period last year. This corresponds to an organic growth in order intake of 38%. It is particularly satisfying to see that order intake from all our brands is growing by at least 35%. The significant increase in order intake is driven by a substantially stronger end market where business has returned after 18 months of lower investment climate and pandemic effects. In addition to the general market recovery, we see temporary effects as our customers rebuild inventories after a weak 2020. There is also an effect of increasing inventories to prepare for longer delivery times for electronic components, due to the semiconductor shortage situation. In total, these effects are estimated to have had a positive effect on orders of approximately SEK 60-70 m during the quarter, which we believe is non-recurring. Sales in the first quarter also increased considerably and amounted to SEK 455 m, an increase of 26% (organic growth is 19%) compared to the corresponding period last year. Despite continued currency headwinds and challenges in sourcing of components, increasing our purchasing costs, we can continue to show a positive development in our gross margin, which amounts to 64.0% (62.4%) for the quarter. The biggest effect behind the strong gross margin is the program that was implemented in 2020 with increased efficiency in operations and selective price increases. The quarter’s operating profit amounts to a record level of SEK 114 m, a significant improvement of 70% compared to the first quarter last year. The positive result is driven by sales growth in combination with good gross margins and continued low operational expenses, partly due to reduced travelling for our staff and reduced external activities due to the pandemic. Cash flow continues to be strong at SEK 132 m (55) in the quarter, which has contributed to reducing our debt. At the end of the quarter, we had a net debt in relation to EBITDA, of 0.21 (1.13). Strong recovery in our main marketsThe biggest contributing factor to the strong quarter has been a continued recovery in our main markets – largely driven by Continental Europe, but China and Japan have also continued to develop well, and on the order side, USA has also shown record levels. Machine builders and device manufacturers in all segments have shown a strong demand for our product offerings. Within Anybus, the German automotive industry, which is an important target group for Anybus sales, has accounted for a large part of the growth through its investments in conversion to electric car production. Also, in Asia growth has been driven by Anybus, largely through the robotics and wind power industry, which takes Asia to new record levels both in terms of sales and order intake. Procentec, which was acquired in the previous quarter, has continued to develop very well, with organic growth of 75% and sales of SEK 52 m, driven by a number of new key customers in Logistics. Roll-out of the HMS 2025 strategyDuring the quarter, we continued the work of implementing the HMS 2025 strategy, presented during the latter part of 2020. Among other things, we strengthened our resources within the important functions M&A and sustainability, two of the main areas in our new strategy. After setting the wheels in motion last year, we have now begun further expansion in China and investments in other interesting markets in Southeast Asia. In the near future, we will also make further investments in building our team for long-term organic growth in Industrial ICT (Information & Communication Technology), towards our goals in 2025: Revenue of more than SEK ”π” (3.14) billion, to be CO2 net positive, and to reach our high ambitions for customer and employee satisfaction. Positive outlook for 2021The recovery has been somewhat faster than we previously expected, and although the first quarter has some positive non-recurring effects, we expect to see continued strong demand in 2021. Of course, there are still uncertainties about what happens with the pandemic, but we assess the risks as lower for each month that passes with more and more people vaccinated. Despite strong demand, we are able to deliver as usual, but we see that our strong order intake in combination with increasing lead times for sourcing semiconductor components means that we can expect certain delivery time increases for customers. The price situation for semiconductors is also expected to increase in the future. As previously communicated, we see increased interest in our offering within Remote Access, which we believe will continue to have a strong market even after the pandemic. We also estimate that our operational expenses will increase during the year with new investments and gradually better conditions for travelling and customer meetings. We continue to work with a focus on long-term growth with a balanced cost level. In the long term, we continue to believe that the market for Industrial ICT (Information & Communication Technology) will be an interesting area, both in terms of organic growth and acquisitions. Halmstad April 23, 2021 Staffan Dahlström Verkställande Direktör Further information can be obtained from: Staffan Dahlström, CEO, +46 (0) 35 17 2901 Joakim Nideborn, CFO, +46 (0) 35 710 6983 This information is such that HMS Networks AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the contact persons set out above, at 08.00 CET on April 23, 2021. HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ixxat®, Ewon® and Intesis® brands. Development takes place at the headquarter in Halmstad and also in Ravensburg, Nivelles, Igualada, Wetzlar Buchen and Delft. Local sales and support are handled by branch offices in Germany, USA, Japan, China, Singapore, Italy, France, Spain, the Netherlands, India, UK, Sweden, South Korea and UAE, as well as through a worldwide network of distributors and partners. HMS employs over 700 people and reported sales of SEK 1,467 million in 2020. HMS is listed on the NASDAQ OMX in Stockholm, category Mid Cap, Information Technology Attachment HMS Networks Q1 Report 2021
Naamloze Vennootschap Nijverheidsstraat 2, 2340 Beerse VAT BE0403.807.337 – RPR Turnhout INVITATION ORDINARY GENERAL MEETING Wednesday 26 May 2021 at 11h Important notification to the shareholders Due to the COVID-19 pandemic, the General Meeting will be organised via electronic communication. The shareholders can only participate via electronic communication (Zoom Video Call). Therefore the shareholders are requested to provide their email address when registering for participation.The shareholders are given the opportunity - in accordance with the modalities below - to ask questions in writing in advance as well as to give a proxy – preferably to the secretary of the General Meeting Ms Karin Leysen - in advance via the proxy form with voting instructions. Practical information regarding the electronic participation can be found on the website: www.campine.com/investors/shareholder information/general meetings. The shareholders are invited to participate in the Ordinary General Meeting, which will be held on Wednesday 26 May 2021 at 11h at Campine, Nijverheidsstraat 2, 2340 Beerse (solely via electronic communication - video call), with the following agenda and proposals: Reading and discussion about the report of the Board of Directors, the annual accounts and consolidated annual accounts of the financial year closed on 31 December 2020. Reading of and discussion about the Auditor’s Report on the above mentioned accounts. Approval of the annual accounts of the financial year closed on 31 December 2020 Resolution proposal: The Ordinary General Meeting approves the annual accounts of the financial year closed on 31 December 2020. Approval of the appropriation of the result of the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting decides to appropriate the result of the financial year closed on 31 December 2020 as proposed by the Board of Directors. The Ordinary General Meeting decides to distribute a dividend of € 0.975 mio (this means € 0.65 gross per share) against presentation of coupon no 12, with payment date: 11 June 2021 (ex-date: 9 June 2021 and record date: 10 June 2021). Approval of the Remuneration Policy of the company.Resolution proposal: The Ordinary General Meeting approves the Remuneration Policy as mentioned in the annual report 2020. 6. Approval of the Remuneration Report of the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting approves the Remuneration Report of the financial year closed on 31 December 2020. 7. Discharge to the Board members for the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting grants discharge to the Board members for the execution of their mandate during the financial year closed on 31 December 2020. Discharge to the Auditor for the financial year closed on 31 December 2020. Resolution proposal: The Ordinary General Meeting grants discharge to the Auditor for the execution of his mandate during the financial year closed on 31 December 2020. Statutory nominations: 9a. Appointment of EY Bedrijfsrevisoren, represented by Harry Everaerts as statutory auditor of the company for a period of 3 years. Article 41 of the EU Regulation 537/2014 states that as of June 17, 2020, a public interest entity shall not grant or renew an audit engagement to a particular statutory auditor or audit firm, if, on the date of entry into force of this regulation, that statutory auditor or audit firm has provided statutory audit services to that public interest organization for a continuous period of twenty or more years. As a result, Deloitte Bedrijfsrevisoren, represented by Luc Van Coppenolle, must resign after the General Meeting in May 2021 that decides on the annual accounts for 2020, given that the indicated term expires at that time. The Board of Directors proposes to appoint EY Bedrijfsrevisoren, represented by Harry Everaerts, as Statutory Auditor for a period of 3 years.Resolution proposal: The Ordinaryl General Meeting relieves Deloitte Bedrijfsrevisoren, represented by Luc Van Coppenolle, from its mandate as statutory auditor from as of the financial year 2021, and grants Deloitte Bedrijfsrevisoren discharge from liability for the exercise of its mandate until May 26, 2021. The Ordinary General Meeting decides, on the proposal of the audit committee, to appoint EY Bedrijfsrevisoren BV, with registered office at De Kleetlaan 2, 1831 Diegem, and registered with the Crossroads Bank for Enterprises under number 0446.334.711 (RPR Brussels), represented by its permanent representative Harry Everaerts Bedrijfsrevisor BV, with registered office at Grote Heimelinkstraat 111, 9100 Sint-Niklaas, represented by its permanent representative, Mr. Harry Everaerts, as statutory auditor of the Company, with immediate effect. The mandate will end at the Ordinary General Meeting to be held in the year 2024. In accordance with article 3:77 of the Companies and Associations Code, the statutory auditor will also audit the consolidated annual accounts of the Company. The fee for the mandate as statutory auditor (both for auditing the statutory and consolidated annual accounts of the Company) amounts to EUR 47,500 per year (indexed annually, excluding VAT and other local taxes, expenses and expenses). 9b. Appointment of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans, as independent Director for a period of 4 years. : The mandate of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans as independent Director ends. Proposal to renew the mandate of FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans as independent Director for a period of 4 years. The Board has determined that YASS BV, represented by its permanent representative Ms Dina Brughmans, complies with all criteria required by the Companies and Associations Code and the Company Code and thus can be considered as an independent Director.Resolution proposal: The Ordinary General Meeting decides to appoint FLG Belgium SRL, represented by its permanent representative Ms Dina Brughmans, as independent Director for a period of 4 years. The mandate ends automatically, unless renewed, after the Annual Meeting held in 2025. The Directors’ remuneration amounts to € 20.500 for 2021. According to the Articles of Association the amount is automatically increased by € 250 on the first day of each new financial year. 9c. Appointment of Mr F.-W. Hempel as Director.: The mandate of Mr F.-W. Hempel ends. Proposal to renew the mandate of Mr F.-W. Hempel as Director for a period of 4 years.Resolution proposal: The Ordinary General Meeting approves the renewal of the mandate of Mr F.-W. Hempel, as Director for a period of 4 years. The mandate ends automatically, unless renewed, after the Annual Meeting held in 2025. The Directors’ remuneration amounts to € 20.500 for 2021. According to the Articles of Association the amount is automatically increased by € 250 on the first day of each new financial year. 10.Any other business Please note that you are required to comply with the following conditions and requirements: CONDITIONS OF ADMISSIONOnly the person who is an official shareholder on the Registration date (Wednesday 12 May 2021 at twenty four (24:00) hour) - either by means of a registration in the Company’s register of shares or by means of a registration on the accounts of the recognised account holders or clearing institution – are admitted to the Ordinary General Meeting, irrespective of the number of shares in his possession on the date of the Ordinary General Meeting. Furthermore, the shareholder confirms his participation to the Ordinary General Meeting ultimately on Thursday 20 May 2021 (16:00). The shareholders are requested to provide their email address when registering: The holder of registered shares: in writing to the company (see contact registered office);The holder of dematerialised shares: to Euroclear Belgium Belgium: due to Covid-19 preferably by email: firstname.lastname@example.org. The recognised account holder, or the clearing institution issues the necessary certificate to the shareholder indicating the total number of dematerialised shares, respectively delivered or registered in his name in his account on the Registration date, with which the shareholder wants to participate in this General Meeting. ADD ITEMS TO THE AGENDAOne or more shareholders holding together at least 3% of the share capital may add items to the agenda of this General Meeting and submit resolution proposals relating to topics already included or to be included on the agenda. These requests must be addressed to the Company (see contact registered office) ultimately on Tuesday 4 May 2021. The shareholders who exercise this right must: prove that on the date of their request, they possess the required percentage of the share capital (by a certificate of registration of the registered shares in the Company's register of shares or by a certificate issued by a recognised account holder or clearing institute indicating that the respective number of dematerialised shares are registered in their name in an account.) and;prove that on the Registration date they are still shareholder holding together at least 3% of the share capital. When appropriate, the revised agenda and adjusted form to vote by proxy will be made public ultimately on 11 May 2021. Nevertheless, the proxies received by the Company prior to the publication of the revised agenda, remain valid for the items mentioned on the agenda. Exceptionally contradictory to the above mentioned, the proxy holder can - in compliance with article 7:130 of the Code on Companies and Associations - during this General Meeting, deviate from possible instructions of the proxy principal, for items mentioned on the agenda, for which new resolutions were submitted, if the execution of these instructions could damage the interest of the proxy principal. The proxy holder has to inform the proxy principal in this case. The proxy should mention whether the proxy holder is entitled to vote on new items put on the agenda or whether he has to abstain from them. RIGHT TO ASK QUESTIONS Pursuant to the Code on Companies and Associations and under certain conditions, the shareholders can submit questions in writing, prior this General Meeting, to the Board or the Auditor regarding their report or items mentioned on the agenda. These questions will be handled during this General Meeting if (i) the shareholder complies with the participation formalities and (ii) as far as the communication of information or facts does not prejudice Campine nv's business interests nor the confidentiality to which Campine nv, its Board of Directors or Auditor have committed themselves.These questions can be submitted in writing or per email beforehand to the Company (see contact registered office ultimately on Thursday 20 May 2021 (16:00h). VOTING BY PROXYEach shareholder who wants to be represented has to comply with the above mentioned registration and confirmation of participation procedures. Each shareholder who complies with the formalities for admission to this General Meeting provided for by the law and the Company's Articles of Association may designate one person – preferably Ms Karin Leysen, secretary of the General Meeting - to represent him at this General Meeting in accordance with the Code on Companies and Associations by means of the form to vote by proxy which can be found on the website www.campine.com/investors/shareholders information/general meetings and is available on request (see contact information registered office). Every appointment of a proxy holder has to be made in compliance with Belgian legislation, especially regarding conflict of interest and the register keeping. The notification of the appointment of a proxy holder must be received ultimately on Thursday 20 May 2021 (16:00h) in writing or by electronic means to the Company (see Contact registered office) or to Euroclear Belgium Belgium: due to Covid-19 preferably by email: email@example.com. FORMALITIESAs of Friday 23 April 2021, the documents to be presented to this General Meeting are available on the website www.campine.com/investors/shareholder information/general meetings and financial publications) or can be consulted at the registered office and are also available – free of charge – on request via letter, fax, tel or email to the registered office attn. Karin Leysen. Contact registered officeCampine nv, Nijverheidsstraat 2, 2340 Beerse, www.campine.comAtt: Karin Leysen: firstname.lastname@example.org, tel: 014/60 15 49 Attachments decision to appoint FLG proxy invitation